Lundin Mining Declares Filo del Sol a “Generational” Discovery, One of the World’s Largest

Lundin Mining (TSX:LUN,OTC Pink:LUNMF) has released an initial resource estimate for the Filo del Sol sulfide deposit, as well as updated resources for the Filo del Sol oxide deposit and the Josemaria deposit. Held in a 50/50 joint venture between Lundin and BHP (ASX:BHP,NYSE:BHP,LSE:BHP), the Argentina-based assets are collectively referred to as the Vicuña resource….

Joe Cavatoni: Gold’s Record Run No Surprise, Here’s What’s Driving Demand

Joe Cavatoni, senior market strategist, Americas, at the World Gold Council, discusses the organization’s latest report on gold demand trends, highlight key data points from Q1. He also shares his thoughts on gold’s record-setting rise, saying fundamentals remain strong. Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this…

Triumph Gold: Multi-million-ounce, District-scale Gold Assets in the Yukon Territory

Triumph Gold (TSXV:TIG,OTC:TIGCF) is a Canadian gold exploration company well-positioned to benefit from a strengthening gold market. The company’s primary focus is advancing its 100 percent-owned Freegold Mountain Project, a district-scale property located in Yukon’s highly prospective Dawson Range gold-copper belt. With defined multi-million ounce gold resources, significant potential for expansion, and promising discovery targets,…

Riverside Resources and Questcorp Mining Execute Definitive Option Agreement for La Union Project, Sonora, Mexico

Riverside Resources Inc. (TSXV: RRI) (OTCQB: RVSDF) (FSE: 5YY) (‘Riverside’ or the ‘Company’), is pleased to announce that further to its press release dated September 6, 2024, Riverside’s wholly-owned subsidiary, RRM Exploracion, S.A.P.I. DE C.V. (the ‘Vendor’) has entered into a definitive option agreement (the ‘Option Agreement’) with Questcorp Mining Inc. (‘Questcorp’) dated May 5,…

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010. Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma…